Jian Shi1, Chen-Lu Lian2, Feng Chi3, Ping Zhou2, Jian Lei4, Li Hua4, Jun Wang2, Zhen-Yu He3, San-Gang Wu2. 1. Division of Breast Surgery, the University of Hong Kong-Shenzhen Hospital, Shenzhen, China. 2. Department of Radiation Oncology, the First Affiliated Hospital of Xiamen University, Xiamen, China. 3. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. 4. Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xiamen University, Xiamen, China.
Abstract
INTRODUCTION: To investigate the prognostic and predictive effect of the American Joint Committee on Cancer (AJCC) 8th edition pathological prognostic staging system in patients with T1-2N1micM0 breast cancer who underwent mastectomy. METHODS: Data from T1-2N1micM0 breast cancer patients who underwent mastectomy from 2010-2014 were obtained from the Surveillance, Epidemiology, and End Results program. The chi-square test, binomial logistics regression, receiver-operating characteristics curve, competing-risk regression model, Cox proportional hazards regression model, and proportional hazard assumption were used for statistical analyses. RESULTS: We identified 4,729 patients, including 1,062 patients were received postmastectomy radiotherapy (PMRT). Stage change occurred in 88.2% of the patients, of which 84.4% were downstaged and 3.7% were upstaged. Patients with higher pathological prognostic stages were independently predicted to receive PMRT. The 5-year breast cancer-specific survival (BCSS) was 97.5, 93.7, 90.1, 86.0, and 73.5% in disease stages IA, IB, IIA, IIB, and IIIA, respectively, according to the 8th edition criteria (P < 0.001). The AJCC 8th edition demonstrated moderate discriminative ability, and it had a significantly better ability to predict the BCSS than the AJCC 7th edition criteria (P < 0.001). The multivariate prognostic analysis showed that the new pathological prognostic staging was an independent prognostic factor affecting the BCSS. The BCSS worsened with an increase in the stage. The PMRT did not affect the BCSS regardless of the pathological prognostic stage. Similar trends were found using the competing-risks regression model. CONCLUSIONS: The 8th AJCC breast cancer pathological prognostic staging system downstaged 84.4% of patients with T1-2N1micM0 disease and the survival outcome prediction with this staging system was more accurate than the AJCC 7th edition system. Our study does not support using the prognostic stage as a guideline to escalate of PMRT.
INTRODUCTION: To investigate the prognostic and predictive effect of the American Joint Committee on Cancer (AJCC) 8th edition pathological prognostic staging system in patients with T1-2N1micM0 breast cancer who underwent mastectomy. METHODS: Data from T1-2N1micM0 breast cancer patients who underwent mastectomy from 2010-2014 were obtained from the Surveillance, Epidemiology, and End Results program. The chi-square test, binomial logistics regression, receiver-operating characteristics curve, competing-risk regression model, Cox proportional hazards regression model, and proportional hazard assumption were used for statistical analyses. RESULTS: We identified 4,729 patients, including 1,062 patients were received postmastectomy radiotherapy (PMRT). Stage change occurred in 88.2% of the patients, of which 84.4% were downstaged and 3.7% were upstaged. Patients with higher pathological prognostic stages were independently predicted to receive PMRT. The 5-year breast cancer-specific survival (BCSS) was 97.5, 93.7, 90.1, 86.0, and 73.5% in disease stages IA, IB, IIA, IIB, and IIIA, respectively, according to the 8th edition criteria (P < 0.001). The AJCC 8th edition demonstrated moderate discriminative ability, and it had a significantly better ability to predict the BCSS than the AJCC 7th edition criteria (P < 0.001). The multivariate prognostic analysis showed that the new pathological prognostic staging was an independent prognostic factor affecting the BCSS. The BCSS worsened with an increase in the stage. The PMRT did not affect the BCSS regardless of the pathological prognostic stage. Similar trends were found using the competing-risks regression model. CONCLUSIONS: The 8th AJCC breast cancer pathological prognostic staging system downstaged 84.4% of patients with T1-2N1micM0 disease and the survival outcome prediction with this staging system was more accurate than the AJCC 7th edition system. Our study does not support using the prognostic stage as a guideline to escalate of PMRT.
Authors: Javaid Iqbal; Ophira Ginsburg; Vasily Giannakeas; Paula A Rochon; John L Semple; Steven A Narod Journal: Breast Cancer Res Treat Date: 2016-10-28 Impact factor: 4.872
Authors: Mariana Chavez-MacGregor; Elizabeth A Mittendorf; Christina A Clarke; Daphne Y Lichtensztajn; Kelly K Hunt; Sharon H Giordano Journal: Oncologist Date: 2017-06-07
Authors: Jose G Bazan; Lonika Majithia; Allison M Quick; Jessica L Wobb; Alicia M Terando; Doreen M Agnese; William Farrar; Julia R White Journal: Ann Surg Oncol Date: 2018-06-18 Impact factor: 5.344
Authors: Donald L Weaver; Takamaru Ashikaga; David N Krag; Joan M Skelly; Stewart J Anderson; Seth P Harlow; Thomas B Julian; Eleftherios P Mamounas; Norman Wolmark Journal: N Engl J Med Date: 2011-01-19 Impact factor: 91.245
Authors: Nienke A de Glas; Mandy Kiderlen; Jan P Vandenbroucke; Anton J M de Craen; Johanneke E A Portielje; Cornelis J H van de Velde; Gerrit-Jan Liefers; Esther Bastiaannet; Saskia Le Cessie Journal: J Natl Cancer Inst Date: 2015-11-26 Impact factor: 13.506
Authors: Abram Recht; Elizabeth A Comen; Richard E Fine; Gini F Fleming; Patricia H Hardenbergh; Alice Y Ho; Clifford A Hudis; E Shelley Hwang; Jeffrey J Kirshner; Monica Morrow; Kilian E Salerno; George W Sledge; Lawrence J Solin; Patricia A Spears; Timothy J Whelan; Mark R Somerfield; Stephen B Edge Journal: Pract Radiat Oncol Date: 2016-09-19
Authors: Anna Weiss; Mariana Chavez-MacGregor; Daphne Y Lichtensztajn; Min Yi; Audree Tadros; Gabriel N Hortobagyi; Sharon H Giordano; Kelly K Hunt; Elizabeth A Mittendorf Journal: JAMA Oncol Date: 2018-02-01 Impact factor: 31.777
Authors: Sae Byul Lee; Guiyun Sohn; Jisun Kim; Il Yong Chung; Jong Won Lee; Hee Jeong Kim; Beom Seok Ko; Byung Ho Son; Sei-Hyun Ahn Journal: Breast Cancer Res Treat Date: 2018-01-31 Impact factor: 4.872